Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Involved in the costimulatory signal essential for T- cell proliferation and IFNG production in a PDCD1-independent manner. Additionally we are shipping PD-L1 Proteins (64) and PD-L1 Kits (25) and many more products for this protein.
Showing 10 out of 300 products:
Human Monoclonal PD-L1 Primary Antibody for FACS, IHC (p) - ABIN1449244
Mandavilli: Hormone in the hot seat. in Nature medicine 2006
Show all 4 references for ABIN1449244
Human Polyclonal PD-L1 Primary Antibody for IF, IHC (p) - ABIN500467
Chentoufi, Kritzer, Tran, Dasgupta, Lim, Yu, Afifi, Jiang, Carpenter, Osorio, Hsiang, Nesburn, Wechsler, BenMohamed: The herpes simplex virus 1 latency-associated transcript promotes functional exhaustion of virus-specific CD8+ T cells in latently infected trigeminal ganglia: a novel immune evasion mechanism. in Journal of virology 2011
Show all 4 references for ABIN500467
Human Polyclonal PD-L1 Primary Antibody for EIA, WB - ABIN401427
Holling, Schooten, van Den Elsen: Function and regulation of MHC class II molecules in T-lymphocytes: of mice and men. in Human immunology 2004
Show all 3 references for ABIN401427
Human Monoclonal PD-L1 Primary Antibody for IHC (p), ELISA - ABIN1995635
Soliman, Khalil, Antonia: PD-L1 expression is increased in a subset of basal type breast cancer cells. in PLoS ONE 2014
Show all 2 references for ABIN1995635
Human Polyclonal PD-L1 Primary Antibody for IHC, ELISA - ABIN185339
Thompson, Gillett, Cheville, Lohse, Dong, Webster, Krejci, Lobo, Sengupta, Chen, Zincke, Blute, Strome, Leibovich, Kwon: Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. in Proceedings of the National Academy of Sciences of the United States of America 2004
Show all 2 references for ABIN185339
Human Monoclonal PD-L1 Primary Antibody for FACS - ABIN2853592
del Rio, Rodriguez-Barbosa, Kremmer, Förster: CD103- and CD103+ bronchial lymph node dendritic cells are specialized in presenting and cross-presenting innocuous antigen to CD4+ and CD8+ T cells. in Journal of immunology (Baltimore, Md. : 1950) 2007
Show all 2 references for ABIN2853592
Mouse (Murine) Monoclonal PD-L1 Primary Antibody for FACS - ABIN317020
Kanai, Totsuka, Uraushihara, Makita, Nakamura, Koganei, Fukushima, Akiba, Yagita, Okumura, Machida, Iwai, Azuma, Chen, Watanabe: Blockade of B7-H1 suppresses the development of chronic intestinal inflammation. in Journal of immunology (Baltimore, Md. : 1950) 2003
Show all 2 references for ABIN317020
Human Monoclonal PD-L1 Primary Antibody for FACS - ABIN1449174
Iwai, Okazaki, Nishimura, Kawasaki, Yagita, Honjo: Microanatomical localization of PD-1 in human tonsils. in Immunology letters 2002
Show all 2 references for ABIN1449174
Data show that Qiyusanlong decoction (QYSL) can moderately inhibit the growth of the transplanted tumor by decreasing programmed death 1 (show PDCD1 Antibodies) and programmed death ligand 1 (PD-1 (show PDCD1 Antibodies)/PD-L1) level.
Expression of PD-L1 is correlated with the severity of periodontitis in the mouse model of experimental periodontitis.
Blockade of TGFbeta (show TGFB1 Antibodies) downregulated PD-1 (show PDCD1 Antibodies) and PD-L1 expression and precipitated graft rejection.
Loss of Cdk5 (show CDK5 Antibodies) results in persistent expression of the PD-L1 transcriptional repressors, the interferon (show IFNA Antibodies) regulatory factors IRF2 (show IRF2 Antibodies) and IRF2BP2 (show IRF2BP2 Antibodies), which likely leads to reduced PD-L1 expression on tumors.
The endogenous PD-1 (show PDCD1 Antibodies)/PD-L pathway does not limit acute experimental foreign antigen-induced circulating immune complex glomerulonephritis.
addition to inhibiting T cells, hepatic stellate cells (HSCs) concurrently inhibit B cells via PD-L1; this direct B cell-inhibitory activity of HSCs should contribute to the mechanism by which HSCs maintain the liver's immune homeostasis
The results demonstrated that blockade of PD-1 (show PDCD1 Antibodies)/B7H1 pathway could promote mouse NK cells to kill the GL261GSCs, and the PD-1 (show PDCD1 Antibodies)-inhibited NK cells could be a feasible immune therapeutic approach against Glioblastoma multiforme.
These findings provide evidence for a novel immune escape mechanism during acute retroviral infection based on PD-L1 expression levels on virus infected target cells
These results suggest a novel and specific role for PspA (show SFTPA1 Antibodies) in modulating immune responses against S. pneumoniae by regulating PD-L1 expression.
Upregulation of PD-1 (show PDCD1 Antibodies) and PD-L1 was associated with marked increases in GADD153 (show DDIT3 Antibodies) during myocardial ischemic reperfusion injury.
Study demonstrates that PD-1 (show PDCD1 Antibodies)(+) TIMC and intratumoral PD-L1(+) expression did not significantly impact tumor aggressiveness or clinical outcome in non-ccRCC specimens.
Immune surveillance is an important mechanism in prevention of cancer development and inhibition of growth of tumors and metastasis. Checkpoint pathways prevent immune response through multiple methods including CTLA-4 (show CTLA4 Antibodies) and PD-1 (show PDCD1 Antibodies)/PD-L1 pathways.A variety of immune checkpoint inhibitors (PD-1 (show PDCD1 Antibodies)/PD-L1 and CTLA-4 (show CTLA4 Antibodies) inhibitors) have been studied in recurrent and metastatic head and neck cancers with encouraging efficacy
n combination with anti-PD-1 (show PDCD1 Antibodies)/PD-L1, the CTLA-4 (show CTLA4 Antibodies)-expanded T cells are prevented from being functionally inhibited when they enter into the tumor microenvironment.
The CTLA-4 (show CTLA4 Antibodies) receptor was one of the first checkpoint inhibitors to be targeted with limited exploration and efficacy in sarcoma.The PD-1 (show PDCD1 Antibodies)/PD-L1 immunologic checkpoint pathway has demonstrated efficacy in many malignancies; studies are ongoing in sarcoma.
High CD274 expression is associated with gliomas.
We provide first evidence that expression of the therapy target PD-L1 is not only highly prevalent in primary prostate cancer cells but is also an independent indicator of BCR (show BCR Antibodies), suggesting a biologic relevance in primary tumors.
High PD-L1 expression is Correlated with Non-Small Cell Lung Cancer.
Overexpression of PDL1 is associated with poor treatment response in esophageal squamous cell carcinoma.
PD-L1-PD-1 (show PDCD1 Antibodies) axis plays a critical role in dampening RFA (show RPA1 Antibodies)-induced antitumor immune responses, and this study provides a strong rationale for combining RFA (show RPA1 Antibodies) and the PD-L1/PD-1 (show PDCD1 Antibodies) blockade in the clinical setting.
smallest amplified 9p24.1 region was restricted to the JAK2-PDL1/2-RANBP6 interval. In the next step, we screened 200 cases of classical Hodgkin lymphoma by interphase FISH and identified PDL1/2 rearrangement (CIITA- and IGH-negative) in four cases (2%), what is a novel finding. Forty (25%) cases revealed high level amplification of 9p24.1
role of programmed death ligand-1 (PD-L1) during porcine circovirus type 2 (PCV2) infection and porcine circovirus associated diseases (PCVAD) development
These data suggest that overexpression of PD-L1 and PD-L2 (show PDCD1LG2 Antibodies) mRNA is one mechanism by which immunosupression of postweaning multisystemic wasting syndrome pigs occurs.
Retinal PLD1 expression is enhanced in radial fibers of Muller cells with age. This finding suggests that PLD1 plays an important role in signal transduction of glial cells and neuronal cells in the retina.
A porcine PD-L1 molecule was cloned using RACE (rapid amplification of cDNA ends) technology and sequenced (GenBank # AY837780); it showed high sequence homology with human PD-L1.
This study provides novel information for the understanding of signalling through PD-L1.
Involved in the costimulatory signal essential for T- cell proliferation and IFNG production in a PDCD1-independent manner. Interaction with PDCD1 inhibits T-cell proliferation by blocking cell cycle progression and cytokine production.
, CD274 antigen
, programmed cell death 1 ligand 1
, programmed cell death ligand 1
, B7 homolog 1
, PDCD1 ligand 1
, programmed death ligand 1